Adrian B McDermott
Overview
Explore the profile of Adrian B McDermott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
9405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Walsh S, Gay C, Karuna S, Hyrien O, Skalland T, Mayer K, et al.
PLoS Med
. 2024 Jun;
21(6):e1004329.
PMID: 38913710
Background: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75%...
12.
Olia A, Prabhakaran M, Harris D, Cheung C, Gillespie R, Gorman J, et al.
Front Immunol
. 2024 Jun;
15:1399960.
PMID: 38873606
The VH6-1 class of antibodies includes some of the broadest and most potent antibodies that neutralize influenza A virus. Here, we elicit and isolate anti-idiotype antibodies against germline versions of...
13.
Ober Shepherd B, Scott P, Hutter J, Lee C, McCauley M, Guzman I, et al.
Lancet Microbe
. 2024 May;
5(6):e581-e593.
PMID: 38761816
Background: A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) has shown protective efficacy in...
14.
Yang Y, Han J, Perrett H, Richey S, Rodriguez A, Jackson A, et al.
Cell Rep
. 2024 May;
43(5):114171.
PMID: 38717904
Influenza A virus subtype H2N2, which caused the 1957 influenza pandemic, remains a global threat. A recent phase 1 clinical trial investigating a ferritin nanoparticle vaccine displaying H2 hemagglutinin (HA)...
15.
Kayentao K, Ongoiba A, Preston A, Healy S, Hu Z, Skinner J, et al.
N Engl J Med
. 2024 Apr;
390(17):1549-1559.
PMID: 38669354
Background: Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled infection in a phase 1 trial. Whether a monoclonal antibody administered subcutaneously can protect children from infection in...
16.
Awan S, Pegu A, Strom L, Carter C, Hendel C, Holman L, et al.
JCI Insight
. 2024 Apr;
9(7).
PMID: 38587079
BACKGROUNDBroadly neutralizing monoclonal antibodies (bNAbs) represent a promising strategy for HIV-1 immunoprophylaxis and treatment. 10E8VLS and VRC07-523LS are bNAbs that target the highly conserved membrane-proximal external region (MPER) and the...
17.
Kosik I, Da Silva Santos J, Angel M, Hu Z, Holly J, Gibbs J, et al.
Sci Immunol
. 2024 Mar;
9(93):eadj9534.
PMID: 38517951
Antigenic drift, the gradual accumulation of amino acid substitutions in the influenza virus hemagglutinin (HA) receptor protein, enables viral immune evasion. Antibodies (Abs) specific for the drift-resistant HA stem region...
18.
deCamp A, Corcoran M, Fulp W, Willis J, Cottrell C, Bader D, et al.
NPJ Vaccines
. 2024 Mar;
9(1):58.
PMID: 38467663
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8...
19.
Lederhofer J, Tsybovsky Y, Nguyen L, Raab J, Creanga A, Stephens T, et al.
Immunity
. 2024 Mar;
57(3):574-586.e7.
PMID: 38430907
Continuously evolving influenza viruses cause seasonal epidemics and pose global pandemic threats. Although viral neuraminidase (NA) is an effective drug and vaccine target, our understanding of the NA antigenic landscape...
20.
Duan H, Corrigan A, Cheng C, Biju A, Gonelli C, Olia A, et al.
iScience
. 2024 Feb;
27(2):108877.
PMID: 38318357
Soluble 'SOSIP'-stabilized HIV-1 envelope glycoprotein (Env) trimers elicit dominant antibody responses targeting their glycan-free base regions, potentially diminishing neutralizing responses. Previously, using a nonhuman primate model, we demonstrated that priming...